Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ionis Pharmaceuticals

28.40
+0.05000.18%
Post-market: 28.400.00000.00%16:25 EDT
Volume:841.01K
Turnover:23.81M
Market Cap:4.51B
PE:-9.35
High:28.76
Open:28.31
Low:28.04
Close:28.35
Loading ...

Ionis Pharmaceuticals Q4 Net Loss Widens, Revenue Falls; 2025 Sales Guidance Set

MT Newswires Live
·
19 Feb

BUZZ-Ionis Pharma rises on better-than-expected quarterly results

Reuters
·
19 Feb

Ionis Pharmaceuticals sees FY25 revenue $600M, consensus $677.05M

TIPRANKS
·
19 Feb

Ionis Pharmaceuticals: Q4 Earnings Snapshot

Associated Press Finance
·
19 Feb

Ionis Pharmaceuticals Forecasts 2025 Revenue Of Over $600M Versus Consensus Of $675.95M

Benzinga
·
19 Feb

Ionis Pharmaceuticals Inc: Sees 2025 Revenue Above $600 Mln

THOMSON REUTERS
·
19 Feb

Ionis Pharmaceuticals Inc Q4 Shr View $-1.12 -- Lseg Ibes Data

THOMSON REUTERS
·
19 Feb

Ionis Pharmaceuticals Inc FY2025 REV View $675.9 Mln -- Lseg Ibes Data

THOMSON REUTERS
·
19 Feb

Ionis Pharmaceuticals Inc Qtrly Shr Loss $0.66

THOMSON REUTERS
·
19 Feb

Ionis Pharmaceuticals Q4 2024 GAAP EPS $(0.66) Beats $(1.10) Estimate, Sales $227.00M Beat $137.60M Estimate

Benzinga
·
19 Feb

BRIEF-Ionis Pharmaceuticals Q4 Revenue USD 227 Million Vs. IBES Estimate USD 137.6 Million

Reuters
·
19 Feb

Ionis Pharmaceuticals Q4 Operating Income USD -110 Million

THOMSON REUTERS
·
19 Feb

Ionis Pharmaceuticals Q4 Adjusted Operating Expenses USD 301 Million

THOMSON REUTERS
·
19 Feb

Ionis Pharmaceuticals Q4 Adjusted Operating Income USD -74 Million VS. Ibes Estimate USD -176.5 Million

THOMSON REUTERS
·
19 Feb

Ionis Pharmaceuticals Q4 Operating Expenses USD 337 Million

THOMSON REUTERS
·
19 Feb

Exploring Analyst Estimates for Ionis Pharmaceuticals (IONS) Q4 Earnings, Beyond Revenue and EPS

Zacks
·
17 Feb

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy?

Zacks
·
12 Feb

Why Insiders Are Selling Ionis Pharmaceuticals, Inc. (IONS) Recently

Insider Monkey
·
12 Feb

Ionis Pharmaceuticals Says Data Readout From Pelacarsen Study Is Delayed

MT Newswires Live
·
01 Feb

Novartis Edges Higher On Sales Beat As Competition Looms For Its Biggest Moneymaker

Blockhead
·
31 Jan